Similar Papers

Paper Title
Journal
Date
Author
Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma.
Sara M Atwa ... Heba Handoussa
World Journal of Hepatology | VOL. 12
Sara M Atwa, et. al.Sara M Atwa ... Heba Handoussa
27 Dec 2020
Relationship between PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Canine Mammary Tumor
Belarmino Eugênio Lopes-Neto ... Fernando Schmitt
Acta Scientiae Veterinariae | VOL. 49
Belarmino Eugênio Lopes-Neto, et. al.Belarmino Eugênio Lopes-Neto ... Fernando Schmitt
01 Jan 2020
Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.
Gordana Vlahovic ... Peter E Fecci
Neuro-Oncology | VOL. 17
Gordana Vlahovic, et. al.Gordana Vlahovic ... Peter E Fecci
10 May 2015
Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?
Justin F Gainor
Cancer cytopathology | VOL. 125
Justin F GainorJustin F Gainor
16 Jun 2017
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Alessio Cortellini ... Biagio Ricciuti
Journal for ImmunoTherapy of Cancer | VOL. 13
Alessio Cortellini, et. al.Alessio Cortellini ... Biagio Ricciuti
04 Feb 2025
Modulating lipid metabolism improves tumor immunotherapy
Yu Ping ... Yi Zhang
Journal for ImmunoTherapy of Cancer | VOL. 13
Yu Ping, et. al.Yu Ping ... Yi Zhang
04 Feb 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Cameron Wood ... Neal Ready
Journal for ImmunoTherapy of Cancer | VOL. 13
Cameron Wood, et. al.Cameron Wood ... Neal Ready
04 Feb 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Thomas Eigentler ... Ulrike Gnad-Vogt
Journal for ImmunoTherapy of Cancer | VOL. 13
Thomas Eigentler, et. al.Thomas Eigentler ... Ulrike Gnad-Vogt
04 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.